Brokerages Set $49.00 Price Target for Celyad SA (NASDAQ:CYAD)
Celyad SA (NASDAQ:CYAD) has been given a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. Celyad SA’s rating score has declined by 67% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokers have set a 1-year consensus price objective of $49.00 for the company and are forecasting that the company will post ($2.02) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Celyad SA an industry rank of 102 out of 265 based on the ratings given to related companies.
Several research analysts have commented on CYAD shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $95.00 target price on shares of Celyad SA in a report on Tuesday, June 7th. Zacks Investment Research raised Celyad SA from a “hold” rating to a “buy” rating and set a $56.00 target price on the stock in a report on Wednesday, May 25th.
An institutional investor recently raised its position in Celyad SA stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Celyad SA (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,161 shares of the company’s stock after buying an additional 3,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.18% of Celyad SA worth $429,000 at the end of the most recent quarter.
Celyad SA (NASDAQ:CYAD) opened at 22.5806 on Monday. Celyad SA has a 52-week low of $19.81 and a 52-week high of $59.50. The firm’s market capitalization is $210.29 million. The stock’s 50 day moving average price is $24.02 and its 200 day moving average price is $37.81.
Celyad SA Company Profile
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with Analyst Ratings Network's FREE daily email newsletter.